352 related articles for article (PubMed ID: 29209918)
1. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.
Yu Y
Front Med; 2018 Apr; 12(2):229-235. PubMed ID: 29209918
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
3. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
5. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
6. Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy.
Ayers M; Nebozhyn M; Cristescu R; McClanahan TK; Perini R; Rubin E; Cheng JD; Kaufman DR; Loboda A
Clin Cancer Res; 2019 Mar; 25(5):1564-1573. PubMed ID: 30442684
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Marcus L; Lemery SJ; Keegan P; Pazdur R
Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
[TBL] [Abstract][Full Text] [Related]
8. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
[TBL] [Abstract][Full Text] [Related]
9. Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial.
Chen J; Quan M; Chen Z; Zeng T; Li Y; Zhou Y; Hai Y; Gao Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2651-2657. PubMed ID: 32623573
[TBL] [Abstract][Full Text] [Related]
10. Making precision oncology the standard of care.
The Lancet Oncology
Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
[No Abstract] [Full Text] [Related]
11. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
Prasad V; Kaestner V
Semin Oncol; 2017 Apr; 44(2):132-135. PubMed ID: 28923211
[TBL] [Abstract][Full Text] [Related]
13. Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
Fernández A
Trends Cancer; 2017 Oct; 3(10):675-677. PubMed ID: 28958385
[TBL] [Abstract][Full Text] [Related]
14. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
Almquist DR; Ahn DH; Bekaii-Saab TS
BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
20. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Dang TO; Ogunniyi A; Barbee MS; Drilon A
Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
